

## ADDITIONAL FILE 13: SUPPLEMENTARY TABLES

### Genetic Determinants Of Anti-Malarial Acquired Immunity In A Large Multi-Centre Study

Jennifer M.G. Shelton, Patrick Corran, Paul Risley, Nilupa Silva, Christina Hubbart, Anna Jeffreys, Kate Rowlands, Rachel Craik, Victoria Cornelius, Meike Hensmann, Sile Molloy, Nuno Sepulveda, Taane G. Clark, Gavin Band, Geraldine M. Clarke, Christopher C.A. Spencer, Angeliki Kerasidou, Susana Campino, Sarah Auburn, Adama Tall, Alioune Badara Ly, Odile Mercereau-Puijalon, Anavaj Sakuntabhai, Abdoulaye Djimde, Boubacar Maiga, Ousmane Toure, Ogobara Doumbo, Amagana Dolo, Marita Troye-Blomberg, Valentina D. Mangano, Frederica Verra, David Modiano, Edith Bougouma, Sodiomon B. Sirima, Muntaser Ibrahim, Ayman Hussain, Nahid Eid, Abier Elzein, Hiba Mohamed, Ahmed Elhassan, Ibrahim Elhassan, Thomas N. Williams, Carolyne Ndila, Alexander Macharia, Kevin Marsh, Alphaxard Manjurano, Hugh Reyburn, Martha Lemnge, Deus Ishengoma, Richard Carter, Nadira Karunaweera, Deepika Fernando, Rajika Dewasurendra, Christopher J. Drakeley, Eleanor M. Riley, Dominic P. Kwiatkowski, and Kirk A. Rockett, in collaboration with the MalariaGEN Consortium,

Corresponding authors Kirk A. Rockett and Dominic P. Kwiatkowski

Wellcome Trust Centre for Human Genetics, University of Oxford, Roosevelt Drive, Oxford, UK

This file contains:

**Additional Table ST7A:** Results of site-specific linear regression analysis investigating the effect of age, gender and malaria status as determined by microscopy on antibody levels to AMA1. Also adjusted for village (>20), ethnicity (>20) and sample month (>20), where data were available for site.

**Additional Table ST7B:** Results of linear regression analysis investigating the effect of age, gender and malaria status as determined by microscopy on antibody levels to MSP1 at each site.

**Additional Table ST7C:** Results of site-specific linear regression analysis investigating the effect of age, gender and malaria status as determined by microscopy on antibody levels to MSP2 at each site. Also adjusted for village (>20), ethnicity (>20) and sample month (>20), where data were available for site.

**Additional Table ST7D:** Results of site-specific linear regression analysis investigating the effect of age, gender and malaria status as determined by microscopy on antibody levels to NANP at each site. Also adjusted for village (>20), ethnicity (>20) and sample month (>20), where data were available for site. Data not available for Tanzania (Moshi).

**Additional Table ST7E:** Results of site-specific linear regression analysis investigating the effect of age, gender and malaria status as determined by microscopy on total IgE levels at each site. Also adjusted for village (>20), ethnicity (>20) and sample month (>20), where data were available for site. Data not available for Tanzania (Moshi).

**Additional Table ST7A:** Results of site-specific linear regression analysis investigating the effect of age, gender and malaria status as determined by microscopy on antibody levels to AMA1. Also adjusted for village (>20), ethnicity (>20) and sample month (>20), where data were available for site.

Factor	Senegal (n=489)		Mali – Pongonon (n=276)		Mali – Manteourou (n=643)		Burkina Faso (n=1827)		Sudan (n=81)	
	beta (95% CI) <sup>b</sup>	p-value	beta (95% CI) <sup>b</sup>	p-value	beta (95% CI) <sup>b</sup>	p-value	beta (95% CI) <sup>b</sup>	p-value	beta (95% CI) <sup>b</sup>	p-value
<i>Age (years)</i>										
<1	0		-		-		0		-	
1-2	-0.02 (-0.86 to 0.83)	0.969	0		-		0.42 (0 to 0.84)	0.052	-	
2-5	0.20 (-0.55 to 0.96)	0.599	-0.40 (-1.24 to 0.44)	0.354	0		<b>1.19 (0.84 to 1.53)</b>	<b>&lt;0.001</b>	-	
5-15	<b>1.11 (0.39 to 1.83)</b>	<b>0.003</b>	-0.25 (-1.08 to 0.59)	0.565	-0.15 (-0.38 to 0.08)	0.193	<b>1.48 (1.16 to 1.81)</b>	<b>&lt;0.001</b>	0	
15-30	<b>1.66 (0.93 to 2.38)</b>	<b>&lt;0.001</b>	0.03 (-1.32 to 1.38)	0.968	-0.10 (-0.35 to 0.15)	0.428	<b>1.16 (0.83 to 1.49)</b>	<b>&lt;0.001</b>	0.15 (-0.30 to 0.61)	0.513
>30	<b>1.43 (0.70 to 2.16)</b>	<b>&lt;0.001</b>	-0.46 (-1.51 to 0.60)	0.396	-0.19 (-0.44 to 0.05)	0.127	<b>0.93 (0.60 to 1.26)</b>	<b>&lt;0.001</b>	0.18 (-0.37 to 0.72)	0.530
<i>Gender</i>										
Female	0		0		0		0		0	
Male	-0.03 (-0.18 to 0.12)	0.693	-0.23 (-0.51 to 0.04)	0.096	0.01 (-0.12 to 0.14)	0.884	<b>-0.12 (-0.22 to -0.03)</b>	<b>0.012</b>	-0.06 (-0.49 to 0.37)	0.793
<i>Microscopy result</i>										
Negative	-		-		0		0		-	
Positive	-		-		-0.13 (-0.28 to 0.03)	0.120	<b>0.13 (0.02 to 0.24)</b>	<b>0.016</b>	-	

Factor	Kenya (n=1808)		Tanzania - Moshi (n=6011)		Tanzania – SP1 (n=536)		Tanzania – SP2 (n=490)		Sri Lanka (n=792)	
	beta (95% CI) <sup>b</sup>	p-value	beta (95% CI) <sup>b</sup>	p-value	beta (95% CI) <sup>b</sup>	p-value	beta (95% CI) <sup>b</sup>	p-value	beta (95% CI) <sup>b</sup>	p-value
<i>Age (years)</i>										
<1	-		0		-		0		-	
1-2	-		0 (-0.11 to 0.10)	0.966	0		-0.13 (-0.95 to 0.69)	0.760	-	
2-5	-		<b>0.13 (0.04 to 0.21)</b>	<b>0.003</b>	0.51 (-0.54 to 1.55)	0.344	-0.12 (-0.64 to 0.39)	0.638	-	
5-15	-		<b>0.39 (0.31 to 0.46)</b>	<b>&lt;0.001</b>	<b>1.19 (0.15 to 2.23)</b>	<b>0.025</b>	<b>0.67 (0.22 to 1.12)</b>	<b>0.004</b>	0	
15-30	-		<b>0.49 (0.41 to 0.57)</b>	<b>&lt;0.001</b>	<b>1.33 (0.25 to 2.41)</b>	<b>0.016</b>	<b>0.83 (0.36 to 1.30)</b>	<b>&lt;0.001</b>	-0.03 (-0.64 to 0.59)	0.932
>30	-		<b>0.56 (0.47 to 0.64)</b>	<b>&lt;0.001</b>	-		0.37 (-0.014 to 0.88)	0.156	0.14 (-0.47 to 0.75)	0.660
<i>Gender</i>										
Female	0		0		0		0		0	
Male	-0.02 (-0.13 to 0.09)	0.725	0.02 (-0.02 to 0.05)	0.322	-0.06 (-0.23 to 0.12)	0.545	<b>-0.27 (-0.44 to -0.10)</b>	<b>0.002</b>	-0.04 (-0.13 to 0.05)	0.407
<i>Microscopy result</i>										
Negative	0		0		0		0		-	
Positive	0.02 (-0.13 to 0.17)	0.775	<b>0.12 (0.08 to 0.17)</b>	<b>&lt;0.001</b>	0.12 (-0.10 to 0.34)	0.273	<b>0.39 (0.21 to 0.58)</b>	<b>&lt;0.001</b>	-	

**Additional Table ST7B:** Results of linear regression analysis investigating the effect of age, gender and malaria status as determined by microscopy on antibody levels to MSP1 at each site.

Factor	Senegal (n=489)		Mali – Pongonon (n=277)		Mali – Manteourou (n=643)		Burkina Faso (n=1827)		Sudan (n=81)	
	beta (95% CI) <sup>b</sup>	p-value	beta (95% CI) <sup>b</sup>	p-value	beta (95% CI) <sup>b</sup>	p-value	beta (95% CI) <sup>b</sup>	p-value	beta (95% CI) <sup>b</sup>	p-value
<i>Age (years)</i>										
<1	0		-		-		0		-	
1-2	0.59 (-0.11 to 1.30)	0.101	0		-		-0.12 (-0.48 to 0.25)	0.528	-	
2-5	<b>0.66 (0.04 to 1.29)</b>	<b>0.037</b>	-0.01 (-0.78 to 0.76)	0.984	0		0.15 (-0.15 to 0.44)	0.333	-	
5-15	<b>0.85 (0.25 to 1.44)</b>	<b>0.005</b>	-0.01 (-0.78 to 0.76)	0.979	-0.03 (-0.33 to 0.26)	0.825	<b>0.47 (0.19 to 0.75)</b>	<b>0.001</b>	0	
15-30	<b>1.39 (0.79 to 1.99)</b>	<b>&lt;0.001</b>	-0.32 (-1.56 to 0.92)	0.612	-0.10 (-0.42 to 0.23)	0.558	<b>0.56 (0.28 to 0.85)</b>	<b>&lt;0.001</b>	0.13 (-0.35 to 0.61)	0.608
>30	<b>1.50 (0.90 to 2.10)</b>	<b>&lt;0.001</b>	-0.28 (-1.29 to 0.73)	0.589	0.03 (-0.30 to 0.36)	0.863	<b>0.71 (0.42 to 1.00)</b>	<b>&lt;0.001</b>	<b>0.56 (0.01 to 1.12)</b>	<b>0.049</b>
<i>Gender</i>										
Female	0		0		0		0		0	
Male	-0.15 (-0.29 to -0.01)	0.040	-0.05 (-0.31 to 0.21)	0.725	-0.06 (-0.24 to 0.11)	0.475	<b>-0.27 (-0.36 to -0.19)</b>	<b>&lt;0.001</b>	-0.25 (-0.69 to 0.19)	0.273
<i>Microscopy result</i>										
Negative	-		-		0		0		-	
Positive	-		-		-0.01 (-0.22 to 0.20)	0.922	0.01 (-0.09 to 0.10)	0.882	-	

Factor	Kenya (n=1808)		Tanzania - Moshi (n=6004)		Tanzania – SP1 (n=536)		Tanzania – SP2 (n=505)		Sri Lanka (n=790)	
	beta (95% CI) <sup>b</sup>	p-value	beta (95% CI) <sup>b</sup>	p-value	beta (95% CI) <sup>b</sup>	p-value	beta (95% CI) <sup>b</sup>	p-value	beta (95% CI) <sup>b</sup>	p-value
<i>Age (years)</i>										
<1	-		0		0		0		-	
1-2	-		-0.12 (-0.24 to 0.01)	0.063	-0.52 (-2.17 to 1.12)	0.532	0.20 (-0.46 to 0.86)	0.553	-	
2-5	-		0.05 (-0.04 to 0.15)	0.262	-0.37 (-1.85 to 1.11)	0.626	-0.27 (-0.71 to 0.17)	0.226	-	
5-15	-		<b>0.34 (0.25 to 0.43)</b>	<b>&lt;0.001</b>	0 (-1.48 to 1.47)	0.997	0.36 (-0.02 to 0.74)	0.061	0	
15-30	-		<b>0.68 (0.59 to 0.78)</b>	<b>&lt;0.001</b>	0.34 (-1.15 to 1.84)	0.652	<b>0.71 (0.31 to 1.10)</b>	<b>&lt;0.001</b>	0.07 (-0.51 to 0.64)	0.825
>30	-		<b>0.85 (0.76 to 0.94)</b>	<b>&lt;0.001</b>	-		<b>0.72 (0.29 to 1.15)</b>	<b>0.001</b>	0.26 (-0.32 to 0.83)	0.378
<i>Gender</i>										
Female	0		0		0		0		0	
Male	-0.03 (-0.10 to 0.05)	0.475	-0.01 (-0.05 to 0.04)	0.776	-0.11 (-0.26 to 0.03)	0.136	<b>-0.35 (-0.49 to -0.21)</b>	<b>&lt;0.001</b>	0.01 (-0.07 to 0.10)	0.737
<i>Microscopy result</i>										
Negative	0		0		0		0		-	
Positive	0.03 (-0.08 to 0.13)	0.602	<b>0.25 (0.19 to 0.31)</b>	<b>&lt;0.001</b>	0.17 (-0.01 to 0.35)	0.059	<b>0.23 (0.07 to 0.39)</b>	<b>0.004</b>	-	

**Additional Table ST7C:** Results of site-specific linear regression analysis investigating the effect of age, gender and malaria status as determined by microscopy on antibody levels to MSP2 at each site. Also adjusted for village (>20), ethnicity (>20) and sample month (>20), where data were available for site.

Factor	Senegal (n=489)		Mali – Pongonon (n=275)		Mali – Manteourou (n=643)		Burkina Faso (n=1824)		Sudan (n=81)	
	beta (95% CI) <sup>b</sup>	p-value	beta (95% CI) <sup>b</sup>	p-value	beta (95% CI) <sup>b</sup>	p-value	beta (95% CI) <sup>b</sup>	p-value	beta (95% CI) <sup>b</sup>	p-value
<i>Age (years)</i>										
<1	0		-		-		0		-	
1-2	0.22 (-0.37 to 0.81)	0.464	0		-		<b>0.52 (0.20 to 0.84)</b>	<b>0.001</b>	-	
2-5	0.33 (-0.20 to 0.86)	0.221	-0.04 (-0.77 to 0.69)	0.913	0		<b>1.11 (0.85 to 1.37)</b>	<b>&lt;0.001</b>	-	
5-15	<b>0.94 (0.44 to 1.44)</b>	<b>&lt;0.001</b>	0.16 (-0.56 to 0.89)	0.658	-0.10 (-0.34 to 0.13)	0.386	<b>1.56 (1.31 to 1.80)</b>	<b>&lt;0.001</b>	0	
15-30	<b>1.48 (0.97 to 1.99)</b>	<b>&lt;0.001</b>	-0.20 (-1.37 to 0.96)	0.733	-0.10 (-0.36 to 0.15)	0.430	<b>1.43 (1.18 to 1.68)</b>	<b>&lt;0.001</b>	0.36 (-0.02 to 0.75)	0.070
>30	<b>1.55 (1.04 to 2.06)</b>	<b>&lt;0.001</b>	-0.14 (-1.05 to 0.77)	0.761	-0.04 (-0.30 to 0.21)	0.739	<b>1.34 (1.09 to 1.59)</b>	<b>&lt;0.001</b>	0.35 (-0.09 to 0.80)	0.126
<i>Gender</i>										
Female	0		0		0		0		0	
Male	-0.02 (-0.14 to 0.10)	0.756	0.10 (-0.13 to 0.34)	0.396	0.10 (-0.03 to 0.24)	0.138	<b>-0.17 (-0.24 to -0.09)</b>	<b>&lt;0.001</b>	-0.25 (-0.60 to 0.11)	0.180
<i>Microscopy result</i>										
Negative	-		-		0		0		-	
Positive	-		-		0.01 (-0.15 to 0.18)	0.867	<b>0.23 (0.14 to 0.31)</b>	<b>&lt;0.001</b>	-	

Factor	Kenya (n=1808)		Tanzania - Moshi (n=6026)		Tanzania – SP1 (n=533)		Tanzania – SP2 (n=491)		Sri Lanka (n=790)	
	beta (95% CI) <sup>b</sup>	p-value	beta (95% CI) <sup>b</sup>	p-value	beta (95% CI) <sup>b</sup>	p-value	beta (95% CI) <sup>b</sup>	p-value	beta (95% CI) <sup>b</sup>	p-value
<i>Age (years)</i>										
<1	-		0		-		0		-	
1-2	-		<b>0.14 (0.03 to 0.25)</b>	<b>0.010</b>	0		-0.03 (-0.77 to 0.71)	0.936	-	
2-5	-		<b>0.19 (0.11 to 0.28)</b>	<b>&lt;0.001</b>	0.05 (-0.61 to 0.70)	0.891	-0.16 (-0.63 to 0.30)	0.486	-	
5-15	-		<b>0.43 (0.35 to 0.51)</b>	<b>&lt;0.001</b>	0.63 (-0.02 to 1.29)	0.057	<b>0.43 (0.02 to 0.83)</b>	<b>0.039</b>	0	
15-30	-		<b>0.61 (0.53 to 0.69)</b>	<b>&lt;0.001</b>	<b>1.10 (0.40 to 1.81)</b>	<b>0.002</b>	<b>0.79 (0.36 to 1.21)</b>	<b>&lt;0.001</b>	0.26 (-0.32 to 0.85)	0.377
>30	-		<b>0.66 (0.58 to 0.74)</b>	<b>&lt;0.001</b>	-		<b>0.49 (0.03 to 0.95)</b>	<b>0.037</b>	0.36 (-0.23 to 0.94)	0.231
<i>Gender</i>										
Female	0		0		0		0		0	
Male	-0.04 (-0.13 to 0.04)	0.339	0.01 (-0.02 to 0.05)	0.427	<b>-0.18 (-0.33 to -0.03)</b>	<b>0.017</b>	<b>-0.21 (-0.36 to -0.06)</b>	<b>0.006</b>	-0.01 (-0.09 to 0.07)	0.823
<i>Microscopy result</i>										
Negative	0		0		0		0		-	
Positive	<b>0.15 (0.03 to 0.26)</b>	<b>0.013</b>	<b>0.16 (0.11 to 0.20)</b>	<b>&lt;0.001</b>	<b>0.29 (0.11 to 0.48)</b>	<b>0.002</b>	<b>0.37 (0.20 to 0.53)</b>	<b>&lt;0.001</b>	-	

**Additional Table ST7D:** Results of site-specific linear regression analysis investigating the effect of age, gender and malaria status as determined by microscopy on antibody levels to NANP at each site. Also adjusted for village (>20), ethnicity (>20) and sample month (>20), where data were available for site. Data not available for Tanzania (Moshi).

Factor	Senegal (n=489)		Mali – Pongonon (n=276)		Mali – Manteourou (n=643)		Burkina Faso (n=1841)		Sudan (n=81)	
	beta (95% CI) <sup>b</sup>	p-value	beta (95% CI) <sup>b</sup>	p-value	beta (95% CI) <sup>b</sup>	p-value	beta (95% CI) <sup>b</sup>	p-value	beta (95% CI) <sup>b</sup>	p-value
<i>Age (years)</i>										
<1	0		-		-		0		-	
1-2	0.21 (-0.26 to 0.67)	0.379	0		-		<b>0.36 (0.09 to 0.62)</b>	<b>0.008</b>	-	
2-5	0.32 (-0.11 to 0.74)	0.143	0.13 (-0.82 to 1.07)	0.795	0		<b>0.60 (0.39 to 0.81)</b>	<b>&lt;0.001</b>	-	
5-15	<b>0.80 (0.40 to 1.21)</b>	<b>&lt;0.001</b>	-0.15 (-1.09 to 0.79)	0.753	0.13 (-0.07 to 0.33)	0.195	<b>1.02 (0.81 to 1.22)</b>	<b>&lt;0.001</b>	0	
15-30	<b>1.06 (0.65 to 1.47)</b>	<b>&lt;0.001</b>	-0.57 (-2.02 to 0.89)	0.448	<b>0.28 (0.06 to 0.49)</b>	<b>0.014</b>	<b>1.24 (1.03 to 1.45)</b>	<b>&lt;0.001</b>	0.19 (-0.07 to 0.45)	0.165
>30	<b>1.35 (0.94 to 1.76)</b>	<b>&lt;0.001</b>	-0.70 (-1.88 to 0.48)	0.247	<b>0.29 (0.07 to 0.51)</b>	<b>0.010</b>	<b>1.44 (1.23 to 1.65)</b>	<b>&lt;0.001</b>	<b>0.50 (0.19 to 0.81)</b>	<b>0.002</b>
<i>Gender</i>										
Female	0		0		0		0		0	
Male	0.05 (-0.04 to 0.14)	0.272	-0.20 (-0.49 to 0.09)	0.177	-0.02 (-0.14 to 0.10)	0.747	<b>-0.10 (-0.16 to -0.03)</b>	<b>0.004</b>	-0.14 (-0.38 to 0.10)	0.269
<i>Microscopy result</i>										
Negative	-		-		0		0		-	
Positive	-		-		0.05 (-0.09 to 0.19)	0.509	0 (-0.08 to 0.07)	0.937	-	

Factor	Kenya (n=1808)		Tanzania – SP1 (n=536)		Tanzania – SP2 (n=494)		Sri Lanka (n=790)	
	beta (95% CI) <sup>b</sup>	p-value	beta (95% CI) <sup>b</sup>	p-value	beta (95% CI) <sup>b</sup>	p-value	beta (95% CI) <sup>b</sup>	p-value
<i>Age (years)</i>								
<1	-		-		0		-	
1-2	-		0		-0.06 (-0.57 to 0.45)	0.816	-	
2-5	-		0.13 (-0.25 to 0.51)	0.505	-0.23 (-0.56 to 0.09)	0.164	-	
5-15	-		0.37 (-0.01 to 0.74)	0.055	0.21 (-0.08 to 0.49)	0.158	0	
15-30	-		<b>0.70 (0.28 to 1.12)</b>	<b>0.001</b>	<b>0.51 (0.21 to 0.80)</b>	<b>0.001</b>	-0.01 (-0.44 to 0.42)	0.957
>30	-		-		0.24 (-0.08 to 0.57)	0.145	0.09 (-0.34 to 0.52)	0.684
<i>Gender</i>								
Female	0		0		0		0	
Male	0.02 (-0.03 to 0.07)	0.486	0 (-0.11 to 0.10)	0.930	-0.02 (-0.12 to 0.09)	0.736	0.05 (-0.01 to 0.11)	0.097
<i>Microscopy result</i>								
Negative	0		0		0		-	
Positive	0.04 (-0.03 to 0.11)	0.236	0.10 (-0.03 to 0.23)	0.149	-0.01 (-0.13 to 0.10)	0.817	-	

**Additional Table ST7E:** Results of site-specific linear regression analysis investigating the effect of age, gender and malaria status as determined by microscopy on total IgE levels at each site. Also adjusted for village (>20), ethnicity (>20) and sample month (>20), where data were available for site. Data not available for Tanzania (Moshi).

Factor	Senegal (n=489)		Mali – Pongonon (n=282)		Mali – Manteourou (n=643)		Burkina Faso (n=1848)		Sudan (n=82)	
	beta (95% CI) <sup>b</sup>	p-value	beta (95% CI) <sup>b</sup>	p-value	beta (95% CI) <sup>b</sup>	p-value	beta (95% CI) <sup>b</sup>	p-value	beta (95% CI) <sup>b</sup>	p-value
<i>Age (years)</i>										
<1	0		-		-		0		-	
1-2	-0.35 (-0.96 to 0.27)	0.268	0		-		-0.09 (-0.41 to 0.22)	0.566	-	
2-5	0.03 (-0.48 to 0.55)	0.894	-0.41 (-0.96 to 0.14)	0.145	0		0.04 (-0.23 to 0.31)	0.761	-	
5-15	0.21 (-0.28 to 0.69)	0.399	-0.49 (-1.04 to 0.05)	0.077	-0.09 (-0.26 to 0.08)	0.309	-0.02 (-0.27 to 0.24)	0.906	0	
15-30	-0.07 (-0.56 to 0.43)	0.795	-0.40 (-1.24 to 0.44)	0.348	-0.08 (-0.27 to 0.11)	0.406	0.09 (-0.16 to 0.35)	0.476	0.21 (-0.40 to 0.81)	0.507
>30	-0.10 (-0.59 to 0.39)	0.690	-0.51 (-1.19 to 0.16)	0.139	-0.06 (-0.25 to 0.13)	0.548	-0.10 (-0.36 to 0.16)	0.431	-0.39 (-1.14 to 0.36)	0.309
<i>Gender</i>										
Female	0		0		0		0		0	
Male	<b>0.15 (0.01 to 0.29)</b>	<b>0.037</b>	0.13 (-0.05 to 0.31)	0.150	-0.06 (-0.16 to 0.04)	0.238	<b>0.17 (0.10 to 0.24)</b>	<b>&lt;0.001</b>	0.47 (-0.10 to 1.04)	0.110
<i>Microscopy result</i>										
Negative	-		-		0		0		-	
Positive	-		-		0.05 (-0.07 to 0.18)	0.383	<b>0.08 (0 to 0.15)</b>	<b>0.041</b>	-	

Factor	Kenya (n=1808)		Tanzania – SP1 (n=509)		Tanzania – SP2 (n=553)		Sri Lanka (n=793)	
	beta (95% CI) <sup>b</sup>	p-value	beta (95% CI) <sup>b</sup>	p-value	beta (95% CI) <sup>b</sup>	p-value	beta (95% CI) <sup>b</sup>	p-value
<i>Age (years)</i>								
<1	-		0		0		-	
1-2	-		0.34 (-0.95 to 1.64)	0.602	0.23 (-0.76 to 1.21)	0.655	-	
2-5	-		0.38 (-0.81 to 1.57)	0.529	-0.04 (-0.54 to 0.47)	0.883	-	
5-15	-		0.73 (-0.46 to 1.92)	0.230	<b>0.51 (0.06 to 0.96)</b>	<b>0.028</b>	0	
15-30	-		0.90 (-0.31 to 2.10)	0.146	<b>0.67 (0.20 to 1.14)</b>	<b>0.005</b>	-0.32 (-0.91 to 0.27)	0.290
>30	-		-		0.45 (-0.05 to 0.96)	0.078	-0.21 (-0.80 to 0.38)	0.483
<i>Gender</i>								
Female	0		0		0		0	
Male	0.01 (-0.06 to 0.07)	0.845	<b>0.13 (0.01 to 0.25)</b>	<b>0.033</b>	<b>0.10 (-0.05 to 0.26)</b>	<b>0.189</b>	<b>0.30 (0.22 to 0.39)</b>	<b>&lt;0.001</b>
<i>Microscopy result</i>								
Negative	0		0		0		-	
Positive	0 (-0.09 to -0.09)	0.989	-0.01 (-0.16 to 0.14)	0.898	0.13 (-0.04 to 0.31)	0.136	-	